In 10 military PTSD patients whose nightmares had not responded to standard treatment, nabilone produced significantly greater nightmare reduction than placebo (CAPS: -3.6 vs -1.0, p=0.03), with 50% rated much improved vs 11% on placebo.
Read this if you have PTSD nightmares that haven't responded to standard treatments, or if you want to understand the evidence behind cannabinoids for PTSD sleep disturbances.
PTSD nightmare scores dropped 3.6x more on nabilone than placebo (p=0.03) — 50% much improved vs 11%
The Backstory
For military veterans with treatment-resistant PTSD, falling asleep is the hardest part. Not because they can't sleep — because they're terrified of what happens when they do. Traumatic memories replay during REM sleep as nightmares so vivid and physiologically real that veterans wake in panic, drenched in sweat, heart racing, sometimes screaming. Many develop a secondary fear: the fear of sleep itself.
The standard treatment, prazosin, doesn't work for everyone. Psychotherapy can't reach a sleeping brain. And so a Canadian military psychiatrist named Rakesh Jetly tested something different: a synthetic cannabinoid called nabilone, designed to suppress the very dreams that torment his patients.
The Trial
Jetly and colleagues at Canadian Forces Health Services designed a small but methodologically rigorous study: a randomized, double-blind, placebo-controlled crossover trial. Ten male Canadian military personnel with PTSD — all of whom had continued to experience trauma-related nightmares despite standard treatment — received either nabilone or placebo for seven weeks, followed by a two-week washout, then switched to the other treatment for another seven weeks.
The crossover design was essential. With only 10 subjects, each person served as his own control — comparing his nightmare frequency on nabilone versus placebo. This dramatically increases statistical power relative to a parallel-group design of the same size.
Nabilone was started at 0.5 mg at bedtime and titrated weekly based on response, up to a maximum of 3.0 mg — the dose at which nightmares were suppressed.
Nabilone vs Placebo
Seven Weeks of Treatment for PTSD Nightmares
-3.6
Nabilone: CAPS nightmare reduction
vs -1.0 for placebo (p=0.03)
50%
Much improved on nabilone
5 of 10 subjects rated 'much improved' on CGI-C
11%
Much improved on placebo
1 of 9 subjects (p=0.05)
+20.8
Wellbeing improvement
General Well Being Questionnaire (p=0.04 vs placebo)
Jetly et al. (2015), Psychoneuroendocrinology 51:585-8
All three primary measures reached statistical significance despite the tiny sample:
The CAPS Recurring and Distressing Dream scores — the gold-standard measure of trauma nightmare severity — dropped 3.6 times more on nabilone than placebo. Global clinical impression showed half of subjects were "much improved" on nabilone versus 11% on placebo. And general wellbeing improved significantly — a measure that captures the downstream effects of finally being able to sleep without terror.
The side effect profile was reassuring: 50% of the nabilone group reported treatment-related adverse events versus 60% on placebo. No adverse event was severe. No one dropped out.
Why Cannabinoids Suppress Nightmares
Biological Mechanism
How Nabilone Stops Trauma Nightmares
PTSD disrupts REM sleep
In PTSD, the normal processing of emotional memories during REM sleep breaks down. Instead of gradual emotional processing, traumatic memories replay as vivid, distressing nightmares — often with full physiological activation (sweating, racing heart, fight-or-flight response).
Nabilone activates CB1 receptors
Nabilone is a synthetic cannabinoid that activates CB1 receptors throughout the brain, including in the amygdala (fear processing) and hippocampus (memory consolidation).
REM sleep is suppressed
CB1 activation reduces the time spent in REM sleep — the sleep stage where dreams and nightmares occur. Less REM means fewer opportunities for traumatic replay.
Emotional memory processing shifts
Beyond simple REM suppression, cannabinoids may modulate fear extinction and emotional memory reconsolidation — potentially reducing the emotional intensity of traumatic memories rather than just suppressing their nighttime replay.
The tradeoff
REM sleep serves important functions (memory consolidation, emotional processing, learning). Chronically suppressing REM has costs. When nabilone is stopped, REM rebound produces temporarily intensified dreams — the vivid dreaming that cannabis users experience when quitting.
Jetly et al. (2015); Fraser (2009)
This is the pharmacological reality that makes cannabinoids both effective and controversial for PTSD nightmares. They work by suppressing the sleep stage where nightmares happen. That's immediate and reliable. But REM sleep exists for a reason, and the long-term consequences of chronic REM suppression aren't fully understood. For veterans who haven't slept through the night in years, the tradeoff feels obvious. For sleep scientists, it's more complicated.
The Canadian Military Adopted It
What happened after the trial is as remarkable as the trial itself.
Based partly on this study and partly on clinical experience at the Operational Trauma and Stress Support Centre (OTSSC) in Ottawa, the Canadian Armed Forces began using nabilone off-label for PTSD-related nightmares — making them one of the first military organizations in the world to officially incorporate a cannabinoid into PTSD treatment protocols.
A follow-up survey of 60 military members who had used nabilone in clinical practice found that prior to starting treatment, they had suffered from PTSD nightmares for an average of seven years. Seventy-three percent reported that nabilone suppressed their nightmares. This wasn't a controlled trial — it was real-world clinical data from a military healthcare system that was desperate enough to try something new and honest enough to track what happened.
The military adoption matters because it signals something beyond academic interest. The Canadian Forces didn't adopt nabilone because of a single 10-person trial. They adopted it because their clinicians were seeing veterans who had exhausted every standard treatment and were still unable to sleep. Nabilone worked where prazosin, SSRIs, CBT for insomnia, and image rehearsal therapy had failed.
The Limitations Are Real
Supporting arguments
- Rigorous design: randomized, double-blind, placebo-controlled crossover — the crossover design maximizes power with a small sample
- All three primary outcomes reached statistical significance despite n=10
- Treatment-resistant population: these patients had failed standard therapies, making any improvement clinically meaningful
- Real-world validation: Canadian Armed Forces adopted nabilone based on this data plus clinical experience, with 73% nightmare suppression in follow-up survey
- Excellent tolerability: no severe adverse events, no dropouts, side effect rate similar to placebo
Limitations and counterarguments
- Only 10 subjects — among the smallest RCTs in the psychiatric literature
- All male military personnel — cannot generalize to female veterans, civilian PTSD, or sexual trauma
- Short duration (7 weeks per period) — no data on long-term efficacy or dependence
- REM rebound on discontinuation: nightmares may return or worsen when nabilone is stopped
- No comparison to prazosin (the standard pharmacological treatment for PTSD nightmares)
- Nabilone is a synthetic THC analogue — unclear if the finding generalizes to plant-derived cannabis
- No large-scale replication as of 2026
Jetly et al. (2015)
The elephant in the room is sample size. Ten subjects, no matter how well controlled, is a fragile foundation for clinical practice. The Canadian military's adoption was justified by clinical urgency, not statistical certainty. A larger trial — ideally comparing nabilone to prazosin, with longer follow-up and diverse PTSD populations — has not been completed.
The dependence question is also unresolved. Nabilone suppresses nightmares, but what happens when you stop? REM rebound produces temporarily intensified vivid dreams — exactly the opposite of what PTSD patients need. Many patients end up on nabilone indefinitely, which raises questions about long-term sleep architecture effects and whether chronic REM suppression has cognitive costs.
For veterans who haven't slept in years, these are acceptable trade-offs. For the broader question of cannabinoids in PTSD treatment, they're open research questions.
Key Takeaways
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study
Jetly R, Heber A, Fraser G, Boisvert D (2015) · Psychoneuroendocrinology
Can cannabis help with PTSD nightmares?
This study tested nabilone (a synthetic cannabinoid), not plant cannabis. The mechanism — CB1 activation suppressing REM sleep — is shared with THC. Many PTSD patients report that cannabis reduces their nightmares, and the pharmacology supports this. But the evidence base for plant cannabis in PTSD is weaker than for nabilone, and chronic use creates dependence with nightmare rebound on cessation.
What is nabilone?
Nabilone (brand name Cesamet) is a synthetic cannabinoid that mimics THC's effects on CB1 receptors. It's approved for chemotherapy-induced nausea and vomiting. Its use for PTSD nightmares is off-label. Unlike plant cannabis, it provides a standardized, controllable dose without the variability of natural products.
Will nightmares come back if I stop nabilone?
Likely, at least temporarily. Cannabinoids suppress REM sleep; when they're discontinued, REM sleep rebounds — producing vivid, sometimes distressing dreams for days to weeks. For PTSD patients, this rebound can be particularly difficult. Many patients who start nabilone for nightmares end up taking it long-term, which raises questions about dependence and chronic REM suppression.
Why hasn't this been replicated in a larger trial?
PTSD nightmare trials face unique challenges: the population is hard to recruit (veterans with treatment-resistant PTSD are a small, highly burdened group), the outcome (nightmare frequency) is inherently subjective, and regulatory barriers around cannabinoid research have slowed progress. As of 2026, no large-scale RCT of nabilone for PTSD nightmares has been published.
What the researchers found
CAPS Recurring Dream scores: nabilone -3.6 (±2.4) vs placebo -1.0 (±2.1), p=0.03. CGI-C: nabilone 1.9 (much improved) vs placebo 3.2 (minimally improved), p=0.05. 50% much improved on nabilone vs 11% on placebo. General wellbeing: +20.8 vs -0.4, p=0.04. No severe adverse events.
Why it matters
This was the first double-blind placebo-controlled RCT of a cannabinoid for PTSD nightmares in military personnel. Despite the tiny sample, all three outcomes reached significance. The Canadian Armed Forces subsequently adopted nabilone for PTSD nightmares — one of the first military organizations to incorporate cannabinoids into mental health treatment.
How the study worked
Randomized, double-blind, placebo-controlled crossover trial. 10 male Canadian military personnel with PTSD and treatment-resistant nightmares. Nabilone started at 0.5 mg, titrated to max 3.0 mg. 7-week treatment periods with 2-week washout. Assessed with CAPS dream subscale, CGI-C, and General Well Being Questionnaire. Registered with Health Canada.
What this study cannot tell us
Only 10 subjects. All male military personnel — cannot generalize to female veterans, civilian PTSD, or sexual trauma. Short duration (7 weeks per period). No comparison to prazosin. No data on long-term dependence or REM rebound. Nabilone is synthetic — unclear generalizability to plant cannabis. No large-scale replication.
How to read the evidence
Double-blind, randomized, placebo-controlled crossover design — strong methodology. But only 10 subjects, no large-scale replication, and short duration.
When this study was published
Published in 2015. Canadian military has used nabilone for PTSD clinically since. No large-scale RCT has been published as of 2026.
The bigger picture
This tiny trial opened a door that changed military psychiatry. The Canadian Armed Forces' adoption of nabilone for PTSD was driven by clinical necessity — veterans had exhausted standard treatments and were unable to sleep. The finding that cannabinoids can suppress trauma nightmares through REM modulation has implications far beyond the military, affecting the millions of civilians with PTSD worldwide.
Questions still open
- Would nabilone work in a larger, more diverse PTSD population? How does it compare to prazosin head-to-head? What are the long-term effects of chronic REM suppression on cognition and emotional processing? Does plant cannabis produce similar nightmare reduction? Can cannabinoids facilitate fear extinction rather than just suppressing REM?
Common questions
Can nabilone help with PTSD nightmares?
What is nabilone?
Will nightmares come back when I stop?
Read the original research
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study.
Psychoneuroendocrinology, 51, 585-588
Citation
Jetly, Rakesh; Heber, Alexandra; Fraser, George; Boisvert, Denis. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study.. Psychoneuroendocrinology, 51, 585-588. https://doi.org/10.1016/j.psyneuen.2014.11.002